MOSCOW (Reuters) – Russia has signed deals to supply South Africa and seven Latin American countries with an anti-viral drug Russian authorities have approved to treat COVID-19, its sovereign wealth fund said on Monday. The Russian Direct Investment Fund (RDIF... More »
BEIJING (Reuters) – China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a v... More »
(Reuters Health) – The cost of new anti-cancer drugs increased more than five-fold from 2006 to 2015, but a new analysis suggests that cancer patients and insurers may be getting less for their money. Anticancer medications account for the lion’s share of glob... More »
(Reuters Health) – Most Americans aren’t aware of cancer drug shortages that might lead some patients to receive less effective or more toxic treatments, a U.S. study suggests. In a nationally representative survey of 420 adults, just 16 percent said they knew... More »
LONDON, (Reuters) – Doctors in France have found the first evidence that a drug normally used to treat lung, kidney or skin cancer may be able to eradicate HIV-infected cells in people with the AIDS virus. In a case described as potentially exciting by scienti... More »
Novartis will seek regulatory approval this year for a new kind of anti-inflammatory heart drug, though some experts fear fatal infection risks and a high price may overshadow the medicine's limited benefits. More »
Shares in Vernalis fell more than 15 percent on Monday as the British biotech company backed by fund manager Neil Woodford and his previous employer Invesco announced a fresh setback for a key new drug in the United States. More »
By Carolyn Crist(Reuters Health) – Cancer patients receiving chemotherapy should have all their medications and herbal supplements reviewed by a phar More »
Israel’s Gamida Cell, which is developing cellular therapies to treat cancer and rare genetic diseases, said on Monday it raised $40 million to finance the advanced trial of its product NiCord to facilitate bone marrow transplants. More »
By Madeline Kennedy(Reuters Health) – As cancer drug costs rise, U.S. cancer patients are more likely than other medical patients to struggle with pa More »
Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, said prescription drug spending for its members slowed to less than 4 percent in 2016, at a time when scrutiny of drug price hikes has intensified. More »
A woman talks on a mobile phone as she walks past the closed research facility of Semler Research Centre in Bengaluru, India, October 13, 2016. REUTERS/Abhishek N. Chinnappa Vasudeva Prakash left his job as a mechanic in Hyderabad three years ago for what he c... More »
Hungarian pharmaceuticals firm Richter has withdrawn its marketing application for one of its biosimilar drugs from the European Medicines Agency in anticipation of a possible negative assessment, the company said on Monday. More »
By Gene Emery(Reuters Health) – Two of the largest suppliers of the life-saving drug naloxone have dramatically increased their prices in recent year More »
Richter received a positive opinion from European regulators recommending that its generic osteoporosis drug Terrosa be granted marketing authorization, the Hungarian drug maker said in a statement on Monday. More »
By Lisa Rapaport(Reuters Health) – Chemotherapy regimens for breast cancer can vary wildly in price even when they are comparable in their ability to More »
By Andrew M. Seaman(Reuters Health) – People with terminal illnesses may legally end their lives with certain medications in the U.S. state of Washi More »
The U.S. Food and Drug Administration has granted priority review for Roche drug Lucentis for treating myopic choroidal neovascularization (mCNV), the Swiss drugmaker said on Tuesday. More »
(Reuters Health) – U.S. doctors and hospitals throw out almost $3 billion (roughly 2.7 billion euros) in unused cancer drugs each year because the medicines come in supersized single-use packages and excess medicine must be discarded for safety reasons, a rece... More »
A new Novartis AG drug to treat heart failure should cost 17 percent less than its list price of $4,560 per year to keep health costs in line with growth in the overall U.S. economy, according to the nonprofit ICER. In a draft report released on Friday, the Bo... More »
